10 research outputs found

    N-substituted benzamides inhibit NFκB activation and induce apoptosis by separate mechanisms

    Get PDF
    Benzamides have been in clinical use for many years in treatment against various disorders. A recent application is that as a sensitizer for radio- or chemotherapies. We have here analysed the mechanism of action of N-substituted benzamides using an in vitro system. We found that while procainamide was biologically inert in our system, the addition of a chloride in the 3′ position of the benzamide ring created a compound (declopramide) that induced rapid apoptosis. Furthermore, declopramide also inhibited NFκB activation by inhibition of IκBβ breakdown. An acetylated variant of declopramide, N-acetyl declopramide, showed no effect with regard to rapid apoptosis induction but was a potent inhibitor of NFκB activation. In fact, the addition of an acetyl group to procainamide in the 4′ position was sufficient to convert this biologically inactive substance to a potent inhibitor of NFκB activation. These findings suggest two potential mechanisms, induction of early apoptosis and inhibition of NFκB mediated salvage from apoptosis, for the biological effect of N-substituted benzamides as radio- and chemo-sensitizers. In addition it suggests that N-substituted benzamides are potential candidates for the development of anti-inflammatory compounds using NFκB as a drug target. © 1999 Cancer Research Campaig

    Surgery and postoperative radiotherapy a valid treatment for advanced oropharyngeal carcinoma

    Get PDF
    Since 1992 we have prospectively included all head and neck cancer patients in our health region in a departmental based register. Our hospital takes care of all head and neck cancer patients in our health region consisting of approximately 1 million people. In 1997, we evaluated the results of the treatment of oropharyngeal cancer in the 1992–1997 period. On the basis of this evaluation, we changed our treatment policy for tonsillar and base of tongue carcinoma. We first changed the treatment for the lesions with worst prognosis, i.e., those with T3–T4 carcinomas, from radiotherapy only, to radical surgery and postoperative radiotherapy. We have since that time increasingly also operated the smaller oropharyngeal carcinomas. The 2 years’ overall survival and disease-specific survival for all patients diagnosed in the 1992–1997 period was 56 and 63%, respectively. The results from a similar group of patients in the 6 years’ period from 2000 to 2005, after the change in treatment, have increased to 83 and 88%. When we looked at the subgroup of patients in the 2000–2005 period treated with surgery and postoperative radiotherapy, 45 out of 69 patients (65%) presenting with an oropharyngeal cancer were fit for operation. With radical surgery and postoperative radiation therapy, the 2 years overall survival is now 91%. The 2-year disease-specific survival is 96% and the locoregional control is 98%. This is a marked improvement as compared to radiotherapy alone and definitely competitive with modern radiochemotherapy

    Komprimirani matriksni dvokomponentni sustavi s metoklopramid hidrokloridom

    Get PDF
    The purpose of the present investigation was to produce a quick/slow biphasic delivery system for metoclopramide hydrochloride using the superdisintegrant Ac-di-sol for the fast release layer and hydroxypropyl methylcellulose K100M and Ucarflock 302 to modulate the release of the drug. A dual component tablet made up of a sustained release and an immediate release layer was prepared by direct compression. A 32 full factorial design was applied to systematically optimize the drug release profile of the sustained release layer. The results of the full factorial design indicate that a small amount of HPMC K100M and a large amount of Ucarflock 302 favor sustained release of the metoclopramide hydrochloride vaginal dual component system. The ex vivo residence time reveals that the formulation was retained for more than 10 h. The formulation gave an initial burst effect to provide the loading dose of the drug followed by sustained release for 12 h, thus solving the problem of repeated administration, especially in pregnancy.Cilj rada bila je priprava brzog/sporog bifazičnog sustava za isporuku metoklopramid hidroklorida koristeći dezintegrator Ac-di-sol za sloj koji brzo oslobađa i hidroksipropil metilcelulozu K100M i Ucarflock 302 za moduliranje oslobađanja ljekovite tvari. Dvokomponentna tableta sa slojem za usporeno i slojem za brzo oslobađanje pripravljena je metodom izravne kompresije. 32 faktorijalni dizajn primijenjen je za sistematsko optimiranje profila oslobađanja ljekovite tvari u sloju za usporeno oslobađanje. Rezultati ukazuju na to da su mala količina HPMC K100M i velika količina Ucarflock 302 bitne za usporeno oslobađanje metoklopramid hidroklorida u dvokomponentnom sustavu za vaginalnu upotrebu. Ex vivo ispitivanja pokazuju da se pripravak zadržava više od 10 h. Naglo oslobađanje lijeka omogućava brzo postizanje udarne doze, a postupno oslobađanje tijekom 12 h održavanje učinkovite koncentracije, čime se rješava problem opetovane primjene, posebno u trudnoći
    corecore